Pioneering TIL, Powering Life.

         领航TIL科技，驱动生命新程

泰生源是深耕细胞领域的创新引擎，专注于肿瘤浸润淋巴细胞（TIL）技术的突破性发展。通过底层核心科技与三级递进管线——天然TIL（TSY-101）、糖工程化TIL（TSY-201）、基因编辑TIL（TSY-301），我们致力于攻克高难度健康挑战，重塑生命科学边界。

构建TIL药物开发、细胞资源库、精准免疫评估、健康管理生态 四大业务支柱，形成“技术研发-应用转化-健康守护”全价值链闭环，推动细胞科技普惠化进程。

TSY drives innovation in cellular therapeutics, pioneering breakthrough Tumor-Infiltrating Lymphocyte (TIL) technology. Leveraging proprietary platforms and atri-level pipeline—Native TIL (TSY-101), Glyco-engineered TIL (TSY-201), Gene-edited  TIL (TSY-301), we target complex health challenges to redefine life science frontiers.

Our integrated model combines TIL Therapeutics,Cellular BioBanking, Precision Immune Profiling, and Health Ecosystem services, creating an end-to-end value chain from discovery to health empowerment, accelerating accessible cell technology.